Austin Dosch, MD

Articles by Austin Dosch, MD

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

ByMichael T. Scott, MD, MBA,Austin Dosch, MD,Nagy Elsayyad, MD,Matthew C. Abramowitz, MD,Arnold M. Markoe, MD,Deukwoo Kwon, PhD,W. Zhao, MD, MS,Michael A. Samuels, MD

September 29th 2015

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Latest Updated Articles

$Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?$
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?
Published: September 29th 2015 | Updated:

Austin Dosch, MD

Articles by Austin Dosch, MD

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma